Generation and characterization of a recombinant chimeric protein (rCpLi) consisting of B-cell epitopes of a dermonecrotic protein from Loxosceles intermedia spider venom  by Mendes, T.M. et al.
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a  b  s  t  r  a  c  t
A  chimeric  protein  was constructed  expressing  three  epitopes  of  LiD1,  a dermonecrotic  toxin  from  the
venom  of Loxosceles  intermedia  spider.  This  species  is  responsible  for a large  number  of accidents  involv-
ing  spiders  in  Brazil.  We  demonstrated  that  the chimeric  protein  (rCpLi)  generated  is  atoxic  and  that
antibodies  previously  developed  in  rabbits  against  synthetic  epitopes  reactive  with  rCpLi  in  ELISA  and
immunoblot  assays.  The  antibody  response  in  rabbits  against  the  rCpLi  was  evaluated  by  ELISA  and  we
have  detected  an  antibody  response  in  all immunized  animals.  Overlapping  peptides  covering  the  amino
acid  sequence  of  the  rCpLi  were  synthesized  on  a cellulose  membrane,  and  their recognition  by  rabbit
anti-rCpLi  serum  assessed.  Three  different  antigenic  regions  were  identiﬁed.  The  percentage  of  inhibi-ecombinant chimeric protein
-cell epitopes
tion of  the  dermonecrotic,  hemorrhagic  and  edematogenic  activities  caused  by the  recombinant  protein
LiD1r in  naïve  rabbits  was  assessed  by  pre-incubation  with  anti-rCpLi  antibodies.  Anti-rCpLi  induced
good  dermonecrotic  and  hemorrhagic  protection.  The  levels  of protection  were  similar  to  the antiboides
anti-LiD1r.  In  summary,  we  have  developed  a polyepitope  recombinant  chimeric  protein  capable  of  induc-
ing multiple  responses  of neutralizing  antibodies  in  a  rabbit  model.  This  engineered  protein  may  be a
promising  candidate  for therapeutic  serum  development  or vaccination.. Introduction
Loxoscelism is the condition resulting from the bite of “brown
piders” from the Loxosceles genus. Clinical manifestations of Lox-
scelism include dermonecrosis, with gravitational spreading at
nd near the bite site, and to a lesser extent with systemic
nvolvement, such as acute renal failure, intravascular hemoly-
is, thrombocytopenia and disseminated intravascular coagulation
1–3]. The spiders of the Loxosceles genus have a worldwide distri-
ution and accidents have been described on all continents [4–6].
he spider species Loxosceles intermedia, Loxosceles laeta and Lox-
sceles gaucho are a group of arachnids with medical importance in
he South and South-east of Brazil [7]. The number of human acci-
ents caused by spiders of the Loxosceles genus in Brazil amounts
o almost 7000 annually [8].Sphingomyelinases D (SMases D), phospholipase D family, der-
onecrotic proteins or Loxtox protein family [9–11] are the main
omponents expressed in Loxosceles spp. venom glands [12] and are
∗ Corresponding author. Tel.: +55 31 34092645; fax: +55 31 34092614.
E-mail address: olortegi@icb.ufmg.br (C. Chávez-Olortegui).
264-410X/$ – see front matter ©  2013 Elsevier Ltd. All rights reserved.
ttp://dx.doi.org/10.1016/j.vaccine.2013.03.048© 2013 Elsevier Ltd. All rights reserved.
responsible for local and systemic effects induced by Loxosceles ven-
oms. SMase D proteins are also the most antigenic/immunogenic
components of the venom [13]. Monoclonal and polyclonal anti-
bodies against Loxosceles crude venoms principally recognize
dermonecrotic proteins [14,15]. Effective anti-Loxosceles anti-
venoms have been produced by immunization with native or
recombinant SMase-D toxins [16–18].
Linear and conformational epitopes mapped from a recom-
binant dermonecrotic protein (rLiD1) from L. intermedia venom
induced antibody responses that efﬁciently neutralize the toxic
effects of these venoms [19–22]. These previous results suggest that
these synthetic non-toxic immunogens could be used for the pro-
duction of therapeutic sera or in vaccination [22]. We  think that the
success of these strategies can be increased by presenting to the
immune system of immunized animals a formulation containing
recombinant or synthetic multi-epitope proteins consisting of the
LiD1epitopes previously determined. Thus, in this work, we  report
the design, production, puriﬁcation and initial immunological char-
acterization of a recombinant chimeric protein (rCpLi), consisting of
three binding epitopes (one conformational and two  linear) of LiD1.
This approach will be a model for the design and development of
non-toxic antigens that can be good candidates for the production
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f a new generation of therapeutic anti-venoms or vaccines against
oxosceles spider venoms.
. Materials and methods
.1. Animals, Loxosceles venoms and rLiD1
Adult New Zealand rabbits (2–2.5 kg) were used and obtained
rom the Escola de Medicina Veterinária of Universidade Federal
e Minas Gerais (UFMG), BH, MG,  Brazil. All animals received
ree access to water and food under controlled environmental
onditions. Animal manipulations were performed according to
he regulations of the UFMG. Loxosceles venoms were provided
y the Centro de Produc¸ ão e Pesquisa de Imunobiológicos (CPPI)
f the State of Paraná, Brazil. The venoms obtained by electric
timulation (15 V) of adult specimens were pooled, centrifuged,
ltered, lyophilized and stored at −20 ◦C before use. Tityus ser-
ulatus scorpions were collected at Belo Horizonte City (Brazil)
nd maintained at the Laboratory of Immunochemistry of the
iochemistry-Immunology Department, of UFMG. The LiD1 cDNA
16] was subcloned in the pET11a vector, expressed in E. coli
nd puriﬁed by reversed-phase HPLC using a C8-Vydac column as
escribed by [19].
.2. Recombinant chimeric protein (rCpLi) construction
The rCpLi was constructed containing epitopes from rLiD1
16]. The continuous epitopes NLGANSIETDVSFDDNANPEYTYHGIP
peptide 27) and CKKYENFNDFLKGLR (peptide 15) [20,21] and one
onformational epitope NCNKNDHLFACW (peptide 12) [22] were
sed for the chimera recombinant production. The DNA was  syn-
hesized with the nucleotide sequence of the three epitopes using
wo glycine codons as spacers between each epitope sequence (ITD
 Integrated DNA Technologies). At the 5′ end and 3′ end of the
ynthetic DNA were added sites for restriction enzymes NcoI and
hoI respectively. The double stranded DNA was subcloned into
he easy cloning vector pGEM (Promega) and subsequently treated
ith restriction enzymes NcoI and XhoI. The DNA fragment was
uriﬁed and cloned into the expression vector pET 26b (Stratagene),
reviously treated with NcoI and XhoI and alkaline phosphatase.
.3. Expression and puriﬁcation of rCpLi
The vector pET 26b containing the DNA fragment of interest was
hemically transformed into bacteria E. coli BL21 for expression.
acterial cultures were grown in 10 mL  2xYT medium containing
anamicin (50 mg/mL) overnight at 37 ◦C and used to inoculate
00 mL  fresh 2xYT medium. When the culture reached a density
f Ab600 = 0.6, the recombinant vector was induced by addition of
PTG (0.6 mM ﬁnal). The cells were grown for an additional 4 h at
7 ◦C, harvested by centrifugation, and suspended in lysis buffer
50 mM phosphate buffer with 500 mM NaCl) containing 4 mg/mL
ysozyme; and incubated for 15 min  at 37 ◦C. The cells were sub-
ected to heat shock (dry ice/water bath at 37 ◦C by 3×), then were
onicated in short pulses (3 pulses of 10 s with 10 s pause between
hem, amplitude 40%) and subjected to centrifugation at 8000 × g.
he bacterial supernatant and pellet were separated on polyacryl-
mide gels by [23]. After electrophoresis, gels were stained with
oomassie Blue G-250. The supernatant containing soluble pro-
ein was used for puriﬁcation of rCpLi on a column of nickel (GE)
n FPLC apparatus according to manufacturer’s speciﬁcations. The
CpLi was submitted to MALDI-TOF-TOF analyses to determine the
olecular mass.31 (2013) 2749– 2755
2.4. Sphingomyelinase activity of rCpLi
Sphingomyelinase activity of rCpLi was determined using the
Amplex® Red sphingomyelinase assay kit (Molecular Probes, Invi-
trogen, USA). Hydrolysis of sphingomyelin was detected indirectly
by measuring Fluorescence with the ﬂuorescence micro plate
reader (Varian, Agilent Technologies, CA, USA) using excitation at
530 nm and detection at 590 nm.
2.5. Antigenic analysis of rCpLi by ELISA and Western blotting
The antigenic cross-reactivity of rCpLi toward the antibod-
ies anti-L. intermedia venom or anti-individual epitopes was
determined by ELISA and immunoblotting techniques. Falcon
microplates (Becton Dickinson, France) were coated overnight at
4 ◦C with 100 L of 5 g/mL solution of rCpLi or L. intermedia venom
in 20 mM sodium bicarbonate buffer, pH 9.6. The assays were per-
formed as described by [24]. Absorbance values were determined at
492 nm with a Titertek Multiscan spectrophotometer. All measure-
ments were made in duplicate. For the Western blot experiments
samples of rCpLi were solubilized in reducing sample buffer and
run on 15% SDS-PAGE [23]. After electrophoresis, the proteins were
transferred to a 0.45 m nitrocellulose membrane [25]. The assays
were performed as described by [15].
2.6. Immunization of rabbits with rCpLi incorporated in liposomes
For the preparation of liposomes containing rCpLi, 100 mg  of
asolectina (Sigma) was dissolved in distilled water (1 mL). rCpLi was
added at the ratio 1:1 (mg  of asolectina/g of rCpLi). The solution
was lyophilized and stored at −20 ◦C until use. After collection of
pre-immune serum, each animal received an initial subcutaneous
injection of 50 g liposome-entrapped rCpLi in aluminum hydrox-
ide (day 1). Control rabbits received 50 g of unrelated protein in
the same condition. Two  similar booster injections (days 15, and
30) and three injections of 100 g (days 37 and 44) were made.
Animals were bled and blood samples were withdrawn one week
after the last injection.
2.7. Indirect ELISA for the determination of anti-rCpLi antibodies
Falcon plates purchased from Becton Dickinson France S.A. were
coated overnight at 4 ◦C with 100 L of a 5 g/mL solution of the
rCpLi, rLiD1 or L. intermedia,  L. gaucho,  L. laeta spider and T. serrulatus
scorpion venoms in 0.02 M sodium bicarbonate buffer, pH 9.6. The
assays were performed as described before (Section 2.5).
2.8. Immunoassays with cellulose-bound peptides
Sets of 39 overlapping pentadecapeptides frame shifted by
two residues corresponding to the amino acid sequence of rCpLi
were prepared on cellulose membranes by Spot synthesis [26].
The membranes were obtained from Intavis (Koln, Germany) and
the F-moc amino acids from Novabiochem. A Multipep robot was
used for peptide synthesis. The immunoassay was  performed as
described in [21]. The anti-rCpLi rabbit serum was  diluted 1:1000
and alkaline–phosphatase conjugated anti-rabbit antibody (Sigma)
was diluted 1:3000.
2.9. Neutralization assays
The dermonecrotic, edema and hemorrhagic activities of rLiD1
were determined as described by [27]. The neutralization of
these activities was  determined in non-immunized rabbits by pre-
incubation, 1 h at 37 ◦C, of 10 g of the rLiD1 (the MND-minimum
necrotizing dose of the rLiD1 used throughout this study was  10 g)
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Fig. 1. Recombinant chimeric protein of Loxosceles intermedia. (A) LiD1 sequence schema showing the position of the three previously mapped epitopes in LiD1 and the multi
epitope antigen that present the three epitopes. Epitope 1, with the sequence NLGANSIETDVSFDDNANPEYTYHGIP, is present in LiD1 in the position 25–51 [20]. Epitope 2,
with  the sequence CYGSKKYENFNDFLKGLR, is in the position 58–72 [19] and ﬁnally the discontinuous epitope 3 (NCNKNDHLFACW) is located close to C-termini of LiD1
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Amplex® Red sphingomyelinase assay kit (Fig. 2).22]. These three segments are linked by the short spacer GG. This gene, correspo
scherichia coli as a fusion product with a His-tag. For cloning, two amino acid residue
f  epitopes used for the construction of chimeric protein in the 3D structure of LiD1
ith 200 g of IgG anti-rCpLi in a ﬁnal volume of 100 L. Incu-
ation of the rLiD1 with pre-immune IgG was performed as a
egative control. Dermonecrosis, edema and hemorrhage activities
ere measured 72 h after injection. The diameters of hemorrhagic
nd edematogenic lesions were measured with a scale meter and
achymeters, respectively.
.10. Molecular modeling
The three epitopes used for the chimera recombinant produc-
ion were localized in the three-dimensional model of LiD1 and
isualized using swiss-pdb viewer package [28]. The LiD1 model
as achieved by utilizing the SMase I dermonecrotic protein (PDB
ccession code: 1XX1) [29] as template and the molecular modeling
ackage Modeller [30] for models generation.
. Results
.1. Design, expression, puriﬁcation and characterization of
himer protein (rCpLi)
We  have previously identiﬁed and characterized three neu-
ralizing epitopes of a dermonecrotic protein (rLiD1) from L.
ntermedia venom [19–22]. The nucleotide sequence of two  linear
pitopes (NLGANSIETDVSFDDNANPEYTYHGIP and CKKYENFND-
LKGLR) was obtained from gene bank [16]. For the conformational
pitope (NCNKNDHLFACW) we used the codon preference of E. coli
o give its nucleotide sequence. We  also used a spacer with two
lycine codons between the epitope sequences (Fig. 1). Sites for
he restriction enzymes Nco I and Xho I were inserted at the 5′ and
′ ends, respectively, of the synthetic gene for further cloning. The
nal encoding gene has chimeric 189 nucleotides and was synthe-
ized single stranded by the company IDT. To obtain the double
tranded gene PCR was performed using primers covering the full to the 3 epitopes was cloned in the plasmid vector pET-26b (+) and expressed in
e added at the N-terminal portion (MG) and C-terminal portion (LE). (B) Localization
sequence of the chimera and using chimeric DNA as a template. The
DNA obtained was puriﬁed and inserted into the expression vec-
tor pET 26b containing a His6-tag in its C-terminus (Stratagene).
The expression of the chimer gene in the pET 26b vector was  per-
formed in E. coli strain BL21 (DE) and produced after 4 h of induction
with IPTG. After cytoplasmic lysis the recombinant protein was
found both in the supernatant and in the pellet, but was  present
at a higher concentration in the pellet, indicating that the protein
was expressed largely in an insoluble form (Supplementary Fig. 1).
rCpLi was puriﬁed from the supernatent using a nickel column on
an FPLC system. A product of the correct size for rCpLi (7.7 kDa)
was identiﬁed using mass spectrometry. The rCpLi did not showFig. 2. Sphingomyelinase activity of the recombinant protein rCpLi. The SMase
activities using different amounts (25, 50, 100 g) of rCpLi were assessed by Amplex
Red  Sphingomyelinase Assay Kit (Invitrogen). The rLiD1 was used as control.
2752 T.M. Mendes et al. / Vaccine 31 (2013) 2749– 2755
Fig. 3. Immunoreactivity of the rCpLi by ELISA and Western blotting. (A) ELISA
showing the reaction of rCpLi and Loxosceles intermedia whole venom against anti-
peptide antibodies and anti-venom L. intermedia. ELISA plates were coated with
5  g/mL solution of each antigen. Sera were diluted at 1:100 and values given are
the  means of duplicates. The absorbance of the samples was  determined at 492 nm.
(B)  Samples were applied to a 15% polyacrylamide SDS gel and recombinant protein
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Table 1
Neutralization in vitro activities. Rabbits were injected i.d. with 1 MND of rLiD1
which was  pre-incubated for 1 h, at 37 ◦C with pre-immune rabbit IgG or immune
rabbit IgG anti-rCpLi (200 g). The neutralization of the dermonecrotic activity,
hemorrhagic area and edema were measured 72 h after the injection. N = 4.
Immunogen Activity inhibition (%) Reference
Dermonecrotic Hemorrhagic Edema
rLiD1 (in vitro) 100 100 70 Felicori et al. [20]
Pep 15 (in vitro) 80 40 40 Felicori et al. [20]as  transferred to a nitrocellulose membrane. The rCpLi was  probed with mouse
ntibody anti-rLiD1 (diluted 1:5000). The molecular weight standard was applied
o lanes 1 and 4.
Supplementary material related to this article found, in the
nline version, at http://dx.doi.org/10.1016/j.vaccine.2013.03.048.
.2. Antigenicity and immunogenicity of the rCpLi
Antigenic functionality of rCpLi and its cross-reactivity toward
ntibodies against L. intermedia venom, rLiD1 or their epitopes was
tudied by ELISA and immunoblot analysis. The interaction of rCpLi
ith four antibodies: rabbit anti-peptide 27, anti-peptide15, anti-
eptide 12 and anti-L. intermedia crude venom was detected by
LISA. As shown in Fig. 3A, the reactivity of rCpLi and L. intermedia
hole venom against anti-peptide antibodies have similar values
absorbance at 490 nm); however anti-L. intermedia serum antibod-
es recognized strongly the whole venom antigens and moderately
he chimeric protein. Western blot analysis (Fig. 3B, lane 3) showed
hat speciﬁc mouse polyclonal antibody anti-rLiD1 reacted with
CpLi. From these results, we conclude that the rCpLi exhibits good
ntigenic properties.
To assess the capacity of rCpLi to stimulate a protective immune
esponse, rCpLi was entrapped into liposomes which were used as
mmunogens in rabbits. One week after the fourth injection, the
eactivity of serum samples toward the rCpLi, rLiD1 protein and Li
hole venom was tested by indirect ELISA (Fig. 4). Serum samples
rom immunized rabbits showed reactivity against rCpLi (Fig. 4A).
CpLi was able to elicit the production of antibodies which were
ross-reactive with the cognate antigen, rLiD1. Similar reactivities
ere obtained with the pool of the two immune sera (Fig. 4B). The
abbit anti-rCpLi antibodies cross-reacted with venom from the L.rCpLi (in vitro) 95 75 10 This paper
intermedia and L. gaucho sub-species, but not with venoms from L.
laeta or T. serrulatus (Fig. 4C).
In order to map  the epitope recognized by the anti-rCpLi anti-
bodies, we  used Spot synthesis to prepare a set of 39 overlapping
peptides (15 residues, frameshifted by 2 residues) corresponding
to the amino acid sequence of the rCpLi. At the end of the syn-
thesis, the peptides remain covalently bound to the membrane
and can be collectively assayed for antibody reactivity. Fig. 5A
shows the binding pattern of a rabbit anti-rCpLi serum with the
overlapping peptides. Three series of peptides were strongly rec-
ognized by antibodies in the N-terminal part (spots 18–22), the
central region (spots 25–30) and in the C-terminal part of the pro-
tein (spots 37–39), indicating that the three continuous epitopes
are displayed on a large part of the protein (Fig. 5B). The binding
was deemed to be speciﬁc since neither the pre-immune rabbit
serum nor the alkaline–phosphatase conjugated anti-rabbit anti-
body showed reactivity with the membrane (results not shown).
3.3. Protective immune response induced by antibodies after
pre-incubation with rLiD1
The ability of anti-rCpLi rabbit IgGs to block the toxic activity
of rLiD1 was assessed by measuring the reduction of three dif-
ferent biological effects induced by rLiD1 in naïve rabbits. The
dermonecrotic, hemorrhagic and edema forming activities were
assessed in rabbits after injection of rLiD1 previously incubated
with serum IgGs from immunized rabbits. As can be seen in Table 1,
72 h after the injections IgGs from immunized rabbits were able to
effectively neutralize the dermonecrotic and hemorrhagic effects.
However, the edema effects were not neutralized by the IgGs from
anti-rCpLi. Previous results derived from rabbits immunized with
the rLiD1 of L. intermedia were used as a neutralization reference
[20]. These rabbits demonstrated 100% protection against necrotic
and hemorrhagic activities and 70% against oedematogenic activ-
ities. Similarly, groups that received the chimeric protein as an
immunogen displayed about 95% protection against necrotic and
75% against hemorrhagic activities. Notably, for reasons that are
not clear to us, inhibition of edema was  particularly low (10%).
For comparative purposes IgGs from rabbits immunized with the
epitope peptide [20], displayed about 50% protection against der-
monecrotic activity, whilst the hemorrhagic and oedematogenic
activities were 40% neutralized. Therefore, antibodies prepared
from rabbits immunized with the chiemeric multiepitopic protein
were protective against the toxic effects of rLiD1 and were more
efﬁcient in their neutralizing properties than antibodies against
individual epitopes.
4. DiscussionThe production of anti-venoms used for therapeutic purposes
in humans is problematic due to the fact that the animals required
for their production suffer from the effects of the venom [31]. In an
attempt to improve these conditions we have identiﬁed alternative
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Fig. 4. Titration of sera from rabbits immunized with the recombinant protein rCpLi. (A) An ELISA plate was pre-coated with rCpLi (5 g/mL) and sera were diluted between
1:100  and 1:3200. (B) ELISA showing the reaction of pool rabbit antibody anti-rCpLi against rLiD1 and rCpLi. Plates were coated with 5 g/mL solution of each antigen.
Anti-rCpLi serum was  tested at 4 different dilutions (1:100; 1:500; 1:2500; 1:12,500). (C) Recognition of the arachnidic venoms (L. intermedia, L. gaucho, L. laeta and Tityus
s 00). T
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terrulatus)  by rabbit antibody anti-rCpLi (dilutions – 1:100; 1:500; 1:2500; 1:12,5
etermined at 492 nm.  N = 2.
on-toxic immunogens [19–22] for the production of anti-sera
gainst Loxosceles spider venoms. Peptide epitopes were identiﬁed
y epitope mapping of LiD1, a dermonecrotic protein found in the
enom of the Brazilian brown spider L. intermedia [16]. LiD1 protein
howed biological toxic activities which were comparable with
he activities evoked by the crude L. intermedia venom [19]. Manyhe values given are the means of duplicates and absorbance of the samples was
reasons justify the use of peptides instead of entire proteins for the
production of anti-venoms. Firstly, unlike toxic antigens, peptide
formulations are not harmful to the immunized animal. Secondly,
the presentation of formulations containing chimeric proteins
consisting of LiD1epitopes to the immune system of immunized
animals can increase the success of immunization protocols.
2754 T.M. Mendes et al. / Vaccine 31 (2013) 2749– 2755
Fig. 5. Binding pattern of a rabbit anti-rCpLi serum with the overlapping peptides. (A) Reactivity of 15-mer overlapping peptides derived from the amino acid sequence of
rCpLi.  Peptides were prepared by the Spot method on cellulose membranes and rabbit anti-rCpLi binding (diluted 1:1000) to cellulose-bound peptides was detected by an
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orresponding to the signal peptide vector pET 26b.
inally, the production of engineered peptides is generally easier
han procuring and preparing crude venom from spiders.
In the present study we present the development of a chimeric
rotein immunogen of LiD1, a dermonecrotic toxin from L. inter-
edia spider venom, the most prevalent species with medical
mportance in Brazil. In our ﬁrst attempt a chimeric protein
onstruct expressing the epitopes NLGANSIETDVSFDDANPEYTY-
GIP comprising residues 25–51, SKKYENFNDFLKGLR comprising
esidues 58–72 and the conformational epitope NCNKNDHLFACW
ere generated by cloning the respective synthetic genes in
ET 26b vector. We  demonstrated that a non-toxic miniprotein
xpressing epitopes of LiD1from Loxosceles spider venoms can be
enerated. This is not in fact the ﬁrst time that a synthetic chimeric,
ulti-epitope immunogen has been constructed for the stimulat-
ng venom toxin-speciﬁc IgGs. A synthetic immunogen consisting
f a string of epitopes identiﬁed in viper venom SVMPs induced
gGs capable of neutralizing the hemorrhagic effects of the venom
32]. ELISA and Immunoblot assays revealed that the mini-protein
isplayed antigenic activity against antibodies anti-individual epi-
opes. Anti-L. intermedia crude venom also reacted with rCpLi. The
ntibody response of each immunized rabbit against the chimeric
rotein rCpLi and recombinant protein rLiD1 were evaluated by
LISA. Through these assays, we were able to detect a good anti-
ody response in both the immunized rabbits. Surprisingly, similar
ntibody reactivity was observed for rCpLi and rLiD1. Rabbits
mmunized with the chimeric construct reacted signiﬁcantly to L.
ntermedia and L. gaucho venom antigens; however no reactivity
as observed with L. laeta, other Loxosceles species or with T. ser-
ulatus scorpion venom. This ﬁnding is not surprising as proteins
imilar to LiD1 from L. intermedia are found in L. gaucho venom
33].eactivity of each peptide recognized by antiserum rCpLi. The ﬁrst 12 peptides are
An experimental approach to map  rCpLi epitopes was  under-
taken. Overlapping peptides covering the sequence of the protein
were synthesized, and their recognition by rabbit anti-rCpLi serum
assessed. Three different antigenic regions were identiﬁed, as
expected. The percentage of inhibition of the dermonecrotic, hem-
orrhagic and oedematogenic activities caused by the recombinant
protein rLiD1 in naïve rabbits was  assessed by pre-incubation with
anti-rLiD1 antibodies and anti-rCpLi chimeric protein antibodies.
IgG puriﬁed from the serum of each group were pre-incubated
with rLiD1. The anti-rLiD1 as well as by the anti-rCpLi antibodies
provided good dermonecrotic protection (100% and 95% respec-
tively). The protection against hemorrhagic and oedematogenic
activities was smaller for the rCpLi antibodies compared to the anti-
rLiDi antibodies. Hemorrhagic protection given by the anti-rLiD1
antibodies was 100%, whereas anti- rCpLi antibodies gave 75% pro-
tection. The oedematogenic activity seems to be more difﬁcult to
neutralize than the other two  studied activities as already observed
in previous studies [20].
In summary, we  have developed a recombinant chimeric protein
immunogen against LiD1, a dermonecrotic toxin of L. interme-
dia spider venom consisting of B-cell epitopes. This polyepitope
miniprotein is capable of inducing multiple responses of neutraliz-
ing antibodies in a rabbit model. Therefore, this engineered protein
may  be a promising candidate for therapeutic serum development
or vaccination in the future.
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